Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC118 + RC148 versus tislelizumab + chemotherapy as first-line treatment for Claudin18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma
CTR20264047Phase 3Active
- Sponsor
- RemeGen
- Start
- Nov 2026
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of RC118, RC148 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by RemeGen. Started Nov 2026; status: active.
02
Drugs
RC118RC148
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20264047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20264047.